Bird & Bird wins for Neuraxpharm in proceedings against Biogen over MS drug

Contacts

matthias meyer module
Dr. Matthias Meyer

Partner
Germany

Based in Düsseldorf, at the seat of one of the most important patent infringement courts in Europe, I am partner in our Intellectual Property Practice Group and a patent practitioner with a focus on specialist technical areas.

daniel misch module
Dr. Daniel Misch, LL.M.

Counsel
Germany

Working as an associate in our intellectual property team in Düsseldorf, I provide advice to our German and multinational clients from various industries and sectors on all matters of IP law, with a special focus on patent litigation and patent licensing.

International law firm Bird & Bird wins for Neuraxpharm in German court proceedings against Biogen over Multiple Sclerosis (‘MS’) drug.

The Regional Court Düsseldorf announced a judgment rejecting the request for preliminary injunction (‘PI’) against sales of Neuraxpharm’s generic MS pharmaceutical “Dimethylfumarate Neuraxpharm” in Germany. The PI request filed by Biogen MA, Inc. (“Biogen”) was based on the allegation that the marketing of “Dimethylfumarate Neuraxpharm” in Germany would infringe the German part of the European Patent EP 2 653 873 B1 (“EP’873”).

Based on presented evidence, the Regional Court held that Biogen failed to establish a ground for the grant of the requested PI. In its judgment rejecting the PI request, the Regional Court Düsseldorf questioned the validity of EP’873 and considered it more likely that EP’873 will be revoked for lack of inventive step in the pending EPO opposition proceedings than that it will be upheld. In this regard, the Regional Court assumed that the daily dosage of 480 mg DMF was not inventive.

Biogen has appealed the judgment, however, the team are optimistic that this decision will be upheld and that it will favourably impact similar PI proceedings filed by Biogen in various other countries against the sale of “Dimethylfumarate Neuraxpharm” on the basis of EP’873. The Bird & Bird team was led by Dr. Matthias Meyer (partner, Intellectual Property) and Dr. Daniel Misch (counsel, Intellectual Property) and was completed by Dr. Ingo Ortel and Dr. Bernd Aechter (both of the patent attorney firm Ter Meer Steinmeister, Munich).

Dr. Matthias Meyer, Intellectual Property partner at Bird & Bird, says: “We are very pleased to have been able to advise Neuraxpharm in this landmark case against Biogen. It is particularly good news that we have been able to help Neuraxpharm stay in the German market, even though original manufacturers are often victorious in patent infringement cases”.

News & Deals

More News & Deals

News

Bird & Bird advises Paladin Capital Group on Constructive Bio’s $58m Series A Financing

Oct 11 2024

Read More

News

Bird & Bird strengthens London Tax practice with the hire of Jesse Dalton as partner

Oct 10 2024

Read More

Deal

Bird & Bird advises Forbion on £35 million Series A Financing in LoQus23 Therapeutics

Oct 10 2024

Read More

News

Bird & Bird signs MindForward Alliance Pledge

Oct 10 2024

Read More

Deal

Bird & Bird advises CapMan and management on the divestment of service business CaPS

Oct 08 2024

Read More

Deal

Bird & Bird advises founders and other shareholders of Criipto on its sale to BankID BankAxept AS

Oct 08 2024

Read More